SCHEMBL1340490

SCHEMBL1340490

CCn1ccc(-c2ccc3c(c2)c2cc(-c4ccc(F)cc4)c(=O)n(C)c2n3C)n1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 1/20 0.36
▸ HTR1A P08908 3/20 0.35
▸ HTR1B P28222 3/20 0.35
▸ DRD4 P21917 1/20 0.35
▸ DRD3 P35462 1/20 0.35
▸ NTRK1 P04629 1/20 0.34
▸ ACSS2 Q9NR19 1/20 0.34
▸ MAPK14 Q16539 4/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ MAT2A P31153 1/20 0.32
▸ SCN4A P35499 1/20 0.32
▸ METAP2 P50579 1/20 0.32
▸ PIK3CA P42336 1/20 0.32
▸ GABRA1 P14867 1/20 0.31
▸ GABRG2 P18507 1/20 0.31
▸ GABRB3 P28472 1/20 0.31
▸ GABRA5 P31644 1/20 0.31
▸ GABRA3 P34903 1/20 0.31
▸ GABRA2 P47869 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1337150 0.90 ACSS2 (0.34) ACSS2
SCHEMBL1339090 0.89 DRD2 (0.35) DRD2HTR1AHTR1BDRD4DRD3
SCHEMBL1338638 0.85 GABRA1 (0.34) ACSS2MAT2AGABRA1GABRG2GABRB3
SCHEMBL1339409 0.82 HSD11B1 (0.36) MAPK14KDM4EGABRA1GABRG2GABRB3
SCHEMBL1338858 0.79 CYP3A4 (0.33) KDM4EGABRA1GABRG2GABRB3GABRA5
SCHEMBL1339171 0.79 KDM4E (0.35) HTR1AHTR1BMAPK14KDM4EGABRA1
SCHEMBL1336985 0.78 MAPK14 (0.37) MAPK14KDM4EPIK3CAGABRA1GABRG2
SCHEMBL1336944 0.77 MAPK14 (0.36) MAPK14KDM4EMETAP2PIK3CAGABRA1
SCHEMBL1338829 0.76 ALDH1A1 (0.47) MAPK14KDM4EPIK3CAGABRA1GABRG2
SCHEMBL1339145 0.76 HPGD (0.39) MAPK14PIK3CAGABRA1GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 DRD2 715/4885HTR1A 736/4885HTR1B 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback